NCT00215384
已完成
2 期
Study in Patients With COPD
Dey1 个研究点 分布在 1 个国家目标入组 35 人2005年9月22日
适应症COPD
概览
- 阶段
- 2 期
- 干预措施
- 未指定
- 疾病 / 适应症
- COPD
- 发起方
- Dey
- 入组人数
- 35
- 试验地点
- 1
- 主要终点
- The primary outcome variable is the measure of lung function.
- 状态
- 已完成
- 最后更新
- 15年前
概览
简要总结
The purpose of this study is to determine which dose of the investigational drug is the most safe and effective compared to the control drug.
研究者
入排标准
入选标准
- •History of COPD and cigarette smoking
排除标准
- •Clinical diagnosis of asthma.
- •Chest X-ray that is diagnostic of a significant pulmonary disease other than COPD
- •Disease of other major organ systems
结局指标
主要结局
The primary outcome variable is the measure of lung function.
次要结局
- Change in lung function will be examined as a secondary outcome, as well as vital signs, physical examination, adverse even reporting, etc.
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study in Patients With COPDCOPDChronic Obstructive Pulmonary DiseaseNCT00215423Dey49
已完成
3 期
Study in Patients With COPDCOPDNCT00215449Dey690
已完成
2 期
Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)COPDNCT00098228Novartis Pharmaceuticals686
已完成
2 期
Study in Patients With AsthmaAsthmaNCT00215358Dey32
已完成
2 期
Study in Patients With AsthmaAsthmaNCT00215371Dey32